There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on aTyr Pharma (LIFE – Research Report), Genfit SA (GNFT – Research Report) and Boston Scientific (BSX – Research Report) with bullish sentiments.
aTyr Pharma (LIFE)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on aTyr Pharma, with a price target of $35.00. The company’s shares closed last Wednesday at $1.62, close to its 52-week low of $1.56.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for aTyr Pharma with a $21.50 average price target, representing a 1219.0% upside. In a report issued on September 12, JonesTrading also reiterated a Buy rating on the stock with a $12.00 price target.
See the top stocks recommended by analysts >>
Genfit SA (GNFT)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Genfit SA today and set a price target of $11.00. The company’s shares closed last Wednesday at $3.72.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Genfit SA has an analyst consensus of Moderate Buy, with a price target consensus of $11.00.
Boston Scientific (BSX)
Barclays analyst Matt Miksic reiterated a Buy rating on Boston Scientific yesterday and set a price target of $59.00. The company’s shares closed last Wednesday at $54.10, close to its 52-week high of $55.38.
According to TipRanks.com, Miksic is a 5-star analyst with an average return of
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $60.67, a 10.9% upside from current levels. In a report released yesterday, Citi also reiterated a Buy rating on the stock with a $63.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LIFE:
- aTyr Pharma presents efzofitimod data
- aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
- aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- aTyr Pharma reports Q2 EPS (22c), consensus (28c)
- aTyr Pharma price target raised to $20 from $13 at Piper Sandler
